The effect of thymoquinone on infantile spasm

Phase 3

• Conditions: Other specified disorders of nervous system in diseases classified elsewhere; Infantile refractory spasm.; G99.8

• Registration Number: IRCT20200131046317N2
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 26 April 2021

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 20

Inclusion Criteria

Infants who, despite receiving at least 5 days of injectable corticotropin with at least one other appropriate drug for the treatment of infantile spasm, have at least 3 seizures per week as spasms or myoclonic
Parental satisfaction

Exclusion Criteria

having liver or kidney disease.
neurodegenerative disease.

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Seizures numbers. Timepoint: At the beginning of the study and weekly for 3 weeks while taking thymoquinone. Method of measurement: Based on parents' reports.